Acadia Pharmaceuticals Inc (ACAD)
EBITDA Growth
-25.01%
Quarterly · Period ending:
ACAD EBITDA Growth
Year-over-year change vs the same period a year earlier
Latest reported-25.01%period ending
Latest reported-25.01%period ending
ACAD Quarterly EBITDA YoY % (-167.30% → -25.01%)
Year-over-year change
High-resolution chart · PNG
ACAD ebitda growth history
Quarterly. Dates are reporting period ends; fiscal years can differ from calendar years.
| Period ending | EBITDA Growth |
|---|---|
| -25.0081% | |
| -77.3056% | |
| 139.6574% | |
| 14.9096% | |
| 8.5352% | |
| 15.8311% | |
| -70.4838% | |
| 182.0627% | |
| 390.2331% | |
| 159.6006% | |
| 202.3242% | |
| -94.6042% | |
| 124.5333% | |
| 60.2758% | |
| 4.6472% | |
| -87.692% | |
| 22.1715% | |
| -70.0973% | |
| 36.1166% | |
| 83.7966% | |
| 1.8897% | |
| 25.8568% | |
| -18.9369% | |
| -90.2881% | |
| 23.2446% | |
| -2.3052% | |
| 16.1355% | |
| 26.0245% | |
| 11.0024% | |
| -60.6589% | |
| 2.5044% | |
| 6.8163% | |
| 5.9264% | |
| 38.6276% | |
| 12.1132% | |
| 9.5307% | |
| 5.7546% | |
| -75.7282% | |
| -70.7881% | |
| -84.6377% | |
| -82.25% | |
| -23.9772% | |
| -59.4672% | |
| -55.9357% | |
| -80.8819% | |
| -125.6768% | |
| -134.9938% | |
| -130.9773% | |
| -137.0804% | |
| -191.2061% | |
| -78.3613% | |
| -353.9529% | |
| -69.3519% | |
| 0.7902% | |
| -28.6525% | |
| 53.0318% | |
| 17.5321% | |
| -9.3265% | |
| -118.02% | |
| -22.2652% | |
| -57.4796% | |
| -6.5765% | |
| 454.9141% | |
| 51.5956% | |
| 66.9948% | |
| 64.3847% | |
| 41.8619% | |
| 44.1178% | |
| 32.0056% | |
| 18.246% | |
| 20.8786% | |
| 14.4414% | |
| -47.0126% | |
| -40.0828% | |
| -32.5535% | |
| -45.2354% | |
| 0.521% | |
| -31.6517% | |
| -29.1251% | |
| 2.1679% | |
| -104.3058% | |
| -80.3968% | |
| -47.8382% | |
| -109.2834% | |
| -11.1908% | |
| 9.896% | |
| 63.1723% | |
| -426.2062% | |
| -173.0696% | |
| -167.3009% |